Trending Up0.0667 (9.2639%)
  • Bid / Lots
    0.7360/ 10
  • Ask / Lots
    0.8000/ 9
  • Open / Previous Close
    0.7000 / 0.7200
  • Day Range
    Low 0.6650
    High 0.7871
  • 52 Week Range
    Low 0.4100
    High 1.0500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.72
09:32 ET130100.69
09:38 ET5000.705
09:41 ET1000.69
09:54 ET5000.705
09:56 ET3000.72
10:08 ET6000.7085
10:14 ET1000.71
10:19 ET37740.72
10:21 ET1000.71001
10:24 ET2000.72
10:44 ET1000.72
10:50 ET3000.72
10:53 ET6000.72
11:02 ET1000.72
11:04 ET16000.72
11:09 ET2000.72
11:11 ET1000.7199
11:20 ET1000.72
11:27 ET7450.7
11:38 ET36950.72
11:47 ET2600.72
11:56 ET14000.7112
12:07 ET25650.72
12:18 ET2420.72
12:23 ET45000.72
12:25 ET45000.72
12:27 ET2000.72
12:30 ET45000.69
12:32 ET79860.69
12:48 ET8220.69
12:57 ET4830.6875
12:59 ET6980.6875
01:03 ET229530.73
01:26 ET8000.75
01:33 ET6500.75
01:44 ET2000.7104
02:02 ET135670.76
02:13 ET6000.76
02:15 ET13230.76
02:20 ET1310.76
02:33 ET1190.775
02:38 ET11000.76
02:45 ET16000.76
02:51 ET28000.76
03:02 ET27000.76
03:03 ET57630.77
03:05 ET93000.7701
03:09 ET42100.77
03:12 ET244850.77
03:20 ET48340.7871
03:34 ET1150.780101
03:38 ET2850.7839
03:50 ET5000.786
03:54 ET1000.7815
03:56 ET14000.78
03:57 ET6760.78
03:59 ET3000.7867
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTLSA
Tiziana Life Sciences Ltd
United StatesLPTX
Leap Therapeutics Inc
United StatesELTX
Elicio Therapeutics Inc
United StatesENTX
Entera Bio Ltd
United StatesBCAB
Bioatla Inc
United StatesMAIA
Maia Biotechnology Inc
As of 2024-06-20

Company Information

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Contact Information

3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB


Executive Chairman of the Board
Gabriele Cerrone
Chief Executive Officer, Chief Scientific Officer, Executive Director
Kunwar Shailubhai
Finance Director
Keeren Shah
Senior Director, CMC and Non - Clinical Development
Jules Jacob
Chief Development Officer
William Clementi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.